Managing Warning and Precautions: Nitisinone Treatment

Introduction

Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, used to treat hereditary tyrosinemia type 1 (HT-1). While it is an effective treatment, it comes with specific warnings and precautions that need to be considered to ensure patient safety and efficacy.

Elevated Plasma Tyrosine Levels

  • Nitisinone treatment may lead to elevated plasma tyrosine levels due to its inhibition of 4-hydroxyphenyl-pyruvate dioxygenase. To mitigate this risk, it is crucial to maintain a concomitant reduction in dietary tyrosine and phenylalanine. One should keep plasma tyrosine levels below 500 micromol/L to avoid adverse effects.
  • One notable adverse effect of increased plasma tyrosine levels is the development of ocular symptoms, including corneal ulcers, opacities, and photophobia. Regular ophthalmologic examinations, especially slit-lamp examinations, should be performed before initiating Nitisinone treatment. If patients develop eye-related symptoms during treatment, immediate reexamination of the eyes and plasma tyrosine measurement is essential.
  • Moreover, elevated tyrosine levels have been associated with variable degrees of intellectual disability and developmental delay. Abrupt changes in neurologic status should be assessed with a clinical laboratory evaluation, including plasma tyrosine levels.
  • Additionally, painful hyperkeratotic plaques on the soles and palms may occur in some patients with elevated plasma tyrosine levels despite dietary restrictions and Nitisinone treatment. Regular assessment of dietary tyrosine and phenylalanine intake is advised for such patients.

Leukopenia and Severe Thrombocytopenia

  • During clinical trials, some patients on Nitisinone and dietary restrictions experienced transient leukopenia, thrombocytopenia, or both. 
  • Monitoring platelet and white blood cell counts during Nitisinone therapy is crucial to manage these potential adverse effects. Adjusting the Nitisinone dosage may help in improving these conditions.

Conclusion

Nitisinone 2 mg or 5 mg or 10 mg is an effective treatment for HT-1, but healthcare providers must be cautious about potential risks and adhere to preventive measures. Monitoring plasma tyrosine levels, conducting regular ophthalmologic examinations, and managing leukopenia and thrombocytopenia are essential for successful Nitisinone treatment. Furthermore, considering the glycerol content in the oral suspension can help minimize adverse reactions and enhance patient compliance and safety.

Note:

One can order Nitisinone capsules online from India to anywhere across the World. To know more about the medication, contact us at info@indiangenericmedicines.com.


Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021232s010lbl.pdf

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more

Trodelvy: All about the drug

Image
Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t
Read more